Rhythm (Nasdaq: IRTC) today announced new results supporting its Zio long-term continuous monitoring (LTCM) ECG patch.

Building on findings from the CAMELOT (Cardiac Ambulatory Monitor EvaLuation ... demonstrates the superiority of Zio’s 14-day, uninterrupted, patch-based monitoring — AVALON extends findings ...

The Zio LTCM service consists of a prescription-only, patch-based ECG monitoring device ... the value of digital engagement alongside ambulatory cardiac monitoring. “Once again, we have strong ...

Advancing Arrhythmia Detection in Japan The Zio ECG Recording and Analysis System consists of a prescription-only, patch-based ECG ... The Cardiac Ambulatory Monitor EvaLuation of Outcomes and ...

The biggest names in cardiac care gathered in San Diego for the Heart Rhythm Society (HRS) 2025 Annual Meeting.

Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory ... Zio System combines an FDA-cleared and CE-marked, wire-free, patch ...

$1.23 last year. Gross margin improved to 68.8% from 66.3% YoY, driven by volume leverage and operational efficiencies in Zio services. Feel unsure about the market’s next move? Copy trade ...

The company continues to focus on expanding its Zio AT product line and is preparing for the FDA submission of its new Zio MCT product in Q3 2025. Additionally, iRhythm anticipates being slightly ...